BioCentury | Aug 1, 2016
Product Development

IGF synergy in cancer

Despite a history of failures in targeting the insulin-like growth factor receptor for cancer, Boehringer Ingelheim GmbH and Eli Lilly and Co. have several hypotheses that support greater cell cycle arrest and the potential to...
BioCentury | Apr 11, 2011
Product Development

Ligand approach to IGF

While drug companies have been targeting insulin-like growth factor-1 receptor since it was first implicated in cancer almost two decades ago, the strategy has yet to bear fruit because of tumor resistance and off-target effects....
Items per page:
1 - 2 of 2